News
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...
There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...
Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
1don MSN
A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...
Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...
USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...
GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...
People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...
Initially developed to treat type-2 diabetes, the drugs have more recently demonstrated a capacity to neutralize patients' ...
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.
A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results